Fermer le menu



  • Presentation of AI-based screening strategy developed to identify a new generation of drug candidates, MaaT034 being the first product from the new range.
  • First-time presentation of in vitro data for MaaT034, a new generation product, demonstrating biological activity that enhanced responses to Immune Checkpoint Inhibitors (ICIs) therapies.


Lire le communiqué de presse

Plus d'infos